Impulse control disorders arising in 3 patients treated with rotigotine

Clinical Neuropharmacology

Volumn 32, Issue 2, 2009, Pages 59-62

  Wingo, Thomas S ^a   Evatt, Marian ^a   Scott, Burton ^b   Freeman, Alan ^a   Stacy, Mark ^b,c  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DUKE UNIVERSITY   (United States)

Author keywords

Dopamine agonist; Dopamine replacement therapy; Hypersexuality; Impulse control disorders; Parkinson disease; Parkinsonism; Pathological gambling; Rotigotine; Wearing off

Indexed keywords

AMANTADINE; CARBIDOPA PLUS LEVODOPA; ENTACAPONE; LEVODOPA; ROTIGOTINE; SELEGILINE; TRIHEXYPHENIDYL;

ADULT; ARTICLE; CASE REPORT; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERSEXUALITY; IMPULSE CONTROL DISORDER; MALE; NAUSEA; PARKINSON DISEASE; PARKINSONISM; PATHOLOGICAL GAMBLING; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SYMPTOMATOLOGY; TRANSVESTISM;

ADULT; DOPAMINE AGONISTS; FEMALE; HUMANS; IMPULSE CONTROL DISORDERS; MALE; MIDDLE AGED; TETRAHYDRONAPHTHALENES; THIOPHENES;

EID: 67749091150     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNF.0b013e3181684542     Document Type: Article

References (35)

1. L-dopa. Adv Neurol 1984;40:259-269.
2. Lieberman A. Managing the neuropsychiatric symptoms of Parkinson's disease. Neurology 1998;50(suppl 6):S33-S38; discussion S44-S38.
3. Mindham RH. Psychiatric symptoms in parkinsonism. J Neurol Neurosurg Psychiatry 1970;33(2):188-191.
4. Mayeux R. Parkinson's disease: a review of cognitive and psychiatric disorders. Neuropsychiatry Neuropsychol Behav Neurol 1990;3(1):11.
5. Tolosa E, Marti MJ, Valldeoriola F, et al. History of levodopa and dopamine agonists in Parkinson's disease treatment. Neurology 1998;50(suppl 6):S2-S10; discussion S44-S18.
6. Goodwin FK. Psychiatric side effects of levodopa in man. JAMA 1971;218(13):1915-1920.
7. Lesser RP, Fahn S, Snider SR, et al. Analysis of the clinical problems in parkinsonism and the complications of long-term levodopa therapy. Neurology 1979;29(pt 1):1253-1260.
8. Factor SA, Molho ES, Podskalny GD, et al. Parkinson's disease: drug-induced psychiatric states. Adv Neurol 1995;65:115-138.
9. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 2000.
10. Cummings JL. Behavioral complications of drug treatment of Parkinson's disease. J Am Geriatr Soc 1991;39(7):708-716.
11. Weintraub D, Siderowf AD, Potenza MN, et al. Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol 2006;63(7):969-973.
12. Klos KJ, Bower JH, Josephs KA, et al. Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy. Parkinsonism Relat Disord 2005;11(6):381-386.
13. Uitti RJ, Tanner CM, Rajput AH, et al. Hypersexuality with antiparkinsonian therapy. Clin Neuropharmacol 1989;12(5):375-383.
14. Molina J, Sainz-Artiga M, Fraile A, et al. Pathologic gambling in Parkinson's disease: a behavioral manifestation of pharmacologic treatment? Mov Disord 2000;15(5):4.
15. Dodd ML, Klos KJ, Bower JH, et al. Pathological gambling caused by drugs used to treat Parkinson disease. Arch Neurol 2005;62(9):1377-1381.
16. Szarfman A, Doraiswamy PM, Tonning JM, et al. Association between pathologic gambling and parkinsonian therapy as detected in the food and drug administration adverse event database. Arch Neurol 2006;63(2):299-300; author reply 300.
17. Lu C, Bharmal A, Suchowersky O. Gambling and Parkinson disease. Arch Neurol 2006;63(2):298.
18. Grosset KA, Macphee G, Pal G, et al. Problematic gambling on dopamine agonists: not such a rarity. Mov Disord 2006;21(12):2206-2208.
19. Avanzi M, Baratti M, Cabrini S, et al. Prevalence of pathological gambling in patients with Parkinson's disease. Mov Disord 2006;21(12):2068-2072.
20. Voon V, Hassan K, Zurowski M, et al. Prospective prevalence of pathologic gambling and medication association in Parkinson disease. Neurology 2006;66(11):1750-1752.
21. Reynolds NA, Wellington K, Easthope SE. Rotigotine in Parkinson's disease. CNS Drugs 2005;19(11):973-981.
22. Jenner P. A novel dopamine agonist for the transdermal treatment of Parkinson's disease. Neurology 2005;65(suppl 1):S3-S5.
23. Watts RL, Wendt J, Nausieda PL, et al. Efficacy, safety, and tolerability of the rotigotine transdermal patch in patients with early-stage, idiopathic Parkinson's disease: a multicenter, multinational, randomized, double-blind, placebo-controlled trial. Mov Disord 2004;19:S258.
24. Watts RL, Lewitt PA, Sommerville KW, et al. Rotigotine transdermal patch (neupro (r)) is efficacious and safe in patients with early-stage, idiopathic Parkinson's disease, regardless of gender, age, duration and severity of disease. Results of a multicenter, randomized, double-blind, placebo-controlled trial. Mov Disord 2005;20:S93.
25. The Parkinson Study Group. A controlled trial of rotigotine monotherapy in early Parkinson's disease. Arch Neurol 2003;60(12):1721-1728.
26. Watts RL, Jankovic J, Waters C, et al. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology 2007;68(4):272-276.
27. Lewitt PA, Chang F-L, Fazzini E, et al. Rotigotine transdermal system in treatment of patients with advanced-stage Parkinson's disease. Eur J Neurol 2005;12(suppl 2):15-16.
28. Quinn NFTSI. Rotigotine transdermal delivery system (TDS) (SPM 962) - a multicenter, double-blind, randomized, placebo-controlled trail to assess the safety and efficacy of rotigotine TDS in patients with advanced Parkinson's disease. Parkinsonism Relat Disord 2001; 7(suppl 1):S66.
29. Driver-Dunckley E, Samanta J, Stacy M. Pathological gambling associated with dopamine agonist therapy in Parkinson's disease. Neurology 2003;61(3):422-423.
30. Kurlan R, Kurlan R. Disabling repetitive behaviors in Parkinson's disease. Mov Disord 2004;19(4):433-437.
31. Avanzi M, Uber E, Bonfa F, et al. Pathological gambling in two patients on dopamine replacement therapy for Parkinson's disease. Neurol Sci 2004;25(2):98-101.
32. Gschwandtner U, Aston J, Renaud S, et al. Pathologic gambling in patients with Parkinson's disease. Clin Neuropharmacol 2001;24(3):170-172.
33. Seedat S, Kesler S, Niehaus DJ, et al. Pathological gambling behaviour: emergence secondary to treatment of Parkinson's disease with dopaminergic agents. Depress Anxiety 2000;11(4):185-186.
34. Delong MR, Wichmann T. Circuits and circuit disorders of the basal ganglia. Arch Neurol 2007;64(1):20-24.
35. Hernandez G, Hamdani S, Rajabi H, et al. Prolonged rewarding stimulation of the rat medial forebrain bundle: neurochemical and behavioral consequences. Behav Neurosci 2006;120(4):888-904.